MBX Biosciences Engages in Key Healthcare Conference Participation
MBX Biosciences, Inc. (Nasdaq: MBX), a prominent clinical-stage biopharmaceutical enterprise dedicated to pioneering precision peptide therapies, is gearing up for an exciting opportunity at a prominent healthcare event. With a focus on addressing endocrine and metabolic disorders, the company's leadership is set to represent MBX at a highly regarded annual conference.
Details of the Annual Healthcare Conference
Kent Hawryluk, the President and Chief Executive Officer, alongside Dr. Sam Azoulay, the Chief Medical Officer, will be participating in this major healthcare conference. This year's gathering is scheduled to take place over three days, providing a platform for industry leaders and innovators to connect.
Conference Highlights
This year’s conference format includes a unique fireside chat session, followed by one-on-one meetings that foster deeper discussions between attendees. Scheduled for December 2, the session is expected to commence at 4:00 p.m. ET and last for approximately twenty-five minutes. Participants can expect to gain insights into MBX's current pipeline and strategic direction.
Live Webcast and Event Access
For those interested in following the event, MBX Biosciences will provide a live webcast available through its official website. Attendees who cannot join live will have the opportunity to access a replay shortly after the conclusion of the presentations. This replay will remain available for a generous period, ensuring ample time for interested parties to catch up.
About MBX Biosciences and Its Innovations
MBX Biosciences is at the forefront of biopharmaceutical innovation, focusing on groundbreaking precision peptide therapies developed through its proprietary PEP™ platform. The company's impressive pipeline includes canvuparatide (MBX 2109), targeting chronic hypoparathyroidism, and imapextide (1416) for post-bariatric hypoglycemia. Both candidates have reached Phase 2 of development, showcasing MBX's commitment to meeting significant medical needs.
Expanding Pipeline and Future Directions
As part of its growth strategy, MBX Biosciences is also developing an extensive obesity treatment portfolio which includes MBX 4291, currently in Phase 1 development. Furthermore, the company is actively exploring other novel candidates through early-stage discovery processes. This proactive approach augurs well for the future, positioning MBX in a dynamic market with substantial unmet medical needs and significant opportunities for impact.
Investor and Media Contact Information
For further inquiries or detailed information about MBX Biosciences, the following contacts are available:
Media Inquiries
Cassidy McClain
Inizio Evoke Comms
Email: cassidy.mcclain@inizioevoke.com
Phone: (619) 694-6291
Investor Inquiries
Jim DeNike
MBX Biosciences
Email: jdenike@mbxbio.com
Frequently Asked Questions
What is the focus of MBX Biosciences?
MBX Biosciences specializes in the discovery and development of precision peptide therapies aimed at treating endocrine and metabolic disorders.
When will MBX Biosciences present at the conference?
They will be discussing their innovations and pipeline on December 2, during a fireside chat session scheduled for 4:00 p.m. ET.
How can I access the live webcast?
The live webcast can be accessed on the MBX Biosciences website within the events section.
What are some products in the MBX pipeline?
The pipeline includes canvuparatide (MBX 2109), imapextide (1416), and several other candidates focused on significant metabolic issues.
Who should I contact for more information?
You can contact Jim DeNike or Cassidy McClain for additional information regarding MBX Biosciences.
